Drug Combination Details
| General Information of the Combination (ID: C71528) | |||||
|---|---|---|---|---|---|
| Name | Epigallocatechin gallate NP Info | + | Ponatinib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Chronic myelogenous leukaemia
[ICD-11: 2A20]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | MPIP1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TGFB2 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | K-562 | CVCL_0004 | Chronic myelogenous leukemia | Homo sapiens | ||
| Experimental
Result(s) |
Synergistic effect of ponatinib and epigallocatechin-3-gallate induces apoptosis in chronic myeloid leukemia cells through altering expressions of cell cycle regulatory genes. | |||||
